Neither is a proven senolytic in people. Quercetin has the better human data — meta-analyses show a 2–3 mmHg blood-pressure reduction, mostly in people who already have hypertension — but its senolytic fame belongs to a drug combination in early trials, not to capsules. Fisetin's headline mouse lifespan result was not replicated by the NIA's own testing program in 2024.
| Compared on | Fisetin | Quercetin |
|---|---|---|
| Evidence grade | Emerging evidence | Moderate evidence |
| What it is | Fisetin is a naturally occurring flavonol (a plant polyphenol) found in strawberries, apples, persimmons, onions, and other fruits and vegetables. | Quercetin is a flavonol, a plant polyphenol found abundantly in onions, apples, berries, capers, and tea. As one of the most common dietary flavonoids, it has antioxidant and anti-inflammatory properties and has been investigated for cardiovascular effects, particularly on blood pressure. |
| Best human evidence | “In a double-blind RCT of 37 colorectal cancer patients on chemotherapy, fisetin 100 mg/day for 7 weeks significantly lowered plasma IL-8 and hs-CRP versus placebo.” Food & function 2018 · PMID 29541713 | “significant reductions both in systolic BP and diastolic BP following supplementation with quercetin” J Am Heart Assoc 2016 · PMID 27405810 |
| Dose / protocol studied | 100 mg/day for 7 weeks in the colorectal-cancer trial that measured inflammatory markers. No senolytic dosing schedule is established for healthy adults. | ≥500 mg/day (blood-pressure effects appear mainly at 500 mg/day and above) |
| Typical listed price | $38.56 | $21.42 |
| Who it suits | Someone who understands they are buying an unproven mechanism and wants the flavonol that screened most potently in the 2018 senolytic work. | Someone with elevated blood pressure who wants a small, well-characterised effect and is not buying the senolytic story. |
| Who should skip it | Anyone expecting senescent-cell clearance: no published trial has demonstrated it, or an aging benefit, in healthy older adults. | Anyone with normal blood pressure — the effect appears mainly in hypertensive participants — or anyone hoping for lipid or glucose changes, where meta-analyses found no meaningful effect. |
| Key caveat | Nearly all senolytic evidence is preclinical, and the 2018 mouse lifespan finding was not replicated by the NIA Interventions Testing Program in 2024. Small human RCTs show anti-inflammatory effects (for example 100 mg/day for 7 weeks in cancer patients), but no published trial has shown senescent-cell clearance or aging benefits in healthy people. Anti-aging use remains speculative pending larger trials. | Meta-analyses show a small (~2–3 mmHg) blood-pressure reduction, mostly in people with hypertension; lipids and glucose show no meaningful effect, and oral bioavailability is poor. The headline 'senolytic' claims come from the dasatinib+quercetin drug combination in early trials — the biggest 2024 trial was negative overall — not from quercetin capsules alone. |
Fisetin lists at about 1.8× the price of Quercetin. Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
Both are dietary flavonols with a senolytic reputation that outruns their human evidence. What separates them is which measured outcome you care about.
Quercetin, at 500 mg/day or above. Two independent meta-analyses of randomized trials found significant reductions in systolic and diastolic pressure, on the order of 2–3 mmHg, most apparent at 500 mg/day and above and in people with hypertension rather than normal pressure.
Fisetin has the only direct human read-out. In a double-blind randomized trial of 37 colorectal-cancer patients on chemotherapy, fisetin 100 mg/day for 7 weeks significantly lowered plasma IL-8 and hs-CRP versus placebo. That is a specific clinical population, not a healthy-aging result.
Neither. Reviewers caution that senolytics should not yet be used outside clinical trials. The dasatinib-plus-quercetin combination cleared senescent cells in a first-in-human trial, but the largest 2024 randomized trial of it was negative overall — and that is a prescription drug pair, not a capsule.
Quercetin is the one with a signal. A 2023 systematic review and meta-analysis reported that quercetin significantly improved OARSI scores in osteoarthritis models. Treat that as a research signal, not a treatment plan.
Fisetin is a flavonol found in strawberries, apples, persimmons and onions, and strawberries are the richest common dietary source. Quercetin is the most abundant flavonol in the diet, concentrated in onions, apples, broccoli and tea.
Neither compound has human evidence strong enough to justify choosing a capsule over the produce aisle — and quercetin's oral bioavailability is poor and variable, which is the likeliest explanation for its small effect sizes.
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“In a double-blind RCT of 37 colorectal cancer patients on chemotherapy, fisetin 100 mg/day for 7 weeks significantly lowered plasma IL-8 and hs-CRP versus placebo.”
“The NIA Interventions Testing Program's rigorous multi-site mouse lifespan study found fisetin did not significantly extend lifespan at the dose and schedule tested - a key non-replication of the 2018 lifespan finding.”
“The 2017 mechanistic study that identified fisetin as a senolytic, showing it selectively induces apoptosis in senescent murine and human cells.”
“significant reductions both in systolic BP and diastolic BP following supplementation with quercetin”
“quercetin significantly lowered both systolic BP and diastolic BP”
“A random-effects meta-analysis was performed on six studies using the Osteoarthritis Research Society International (OARSI) scoring system, revealing that quercetin significantly improved OA cartilage OARSI scores (SMD, -6.30 [95% CI, -9.59 to -3.01]; P = 0.0002; heterogeneity: I2 = 86%).”
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
In laboratory screening, fisetin was the most potent senolytic among the flavonoids tested. In humans, neither has been shown to clear senescent cells. The strongest senolytic human data belong to the dasatinib-plus-quercetin drug combination, and its largest 2024 trial was negative overall.
In mice, in a 2018 study. The NIA Interventions Testing Program's rigorous multi-site mouse lifespan study later found fisetin did not significantly extend lifespan at the dose and schedule it tested — a key non-replication.
They are frequently combined in senolytic protocols circulating online, but no human trial has tested that combination for senescent-cell clearance or aging outcomes. Both are dietary flavonols with good tolerability at typical doses; talk to your clinician, especially if you take medication.
Meta-analysis effects appear mainly at 500 mg/day and above, and mainly in people who already have hypertension. The reduction is small — around 2–3 mmHg.
Creatine, unless you cannot train. It is the only compound in this pair graded Strong: meta-analyses of…
Neither, on current human evidence. Spermidine's most rigorous trial — twelve months at the 0.9 mg/day dose…
Glycinate, for almost everyone. Magnesium's blood-pressure and sleep evidence is a mineral effect, and…